Market capitalization | CHF544.04m |
Enterprise Value | CHF531.15m |
P/E (TTM) P/E ratio | 7.00 |
EV/FCF (TTM) EV/FCF | 7.31 |
EV/Sales (TTM) EV/Sales | 2.55 |
P/S ratio (TTM) P/S ratio | 2.61 |
P/B ratio (TTM) P/B ratio | 6.72 |
Revenue growth (TTM) Revenue growth | 32.30% |
Revenue (TTM) Revenue | CHF208.54m |
As a Free StocksGuide user, you can view scores for all 6,786 stocks worldwide.
4 Analysts have issued a Basilea Pharmaceutica forecast:
4 Analysts have issued a Basilea Pharmaceutica forecast:
Dec '24 |
+/-
%
|
||
Revenue | 209 209 |
32%
32%
|
|
Gross Profit | 170 170 |
30%
30%
|
|
EBITDA | 65 65 |
185%
185%
|
EBIT (Operating Income) EBIT | 61 61 |
219%
219%
|
Net Profit | 78 78 |
642%
642%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.
Head office | Switzerland |
CEO | David Veitch |
Employees | 164 |
Founded | 2000 |
Website | www.basilea.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.